Krystal Biotech Inc (KRYS) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Krystal Biotech Inc   (NASDAQ: KRYS)

Krystal Biotech Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Krystal Biotech Inc in the second quarter 2026?
Krystal Biotech Inc achieved a return on average equity (ROE) of 19.34 % in its second quarter 2026, this is above KRYS's average return on equity of -5.78%.
Krystal Biotech Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $1,248 million

While the company's net income was fading, Krystal Biotech Inc was able to improve its ROE compared to the first quarter 2026.

Within the Biotechnology & Pharmaceuticals industry 11 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 694, from total ROE ranking in the first quarter 2026 at 704.

What is ROE?




Return On Equity (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Equity Change 30.6 % 29.66 % 28.87 % 28.45 % -
Y / Y Net Income Change 42.87 % 56.53 % 13.02 % 192 % 146.23 %
Net Income (TTM) in Millions 241 225 205 199 147
Return On Equity (TTM) 19.34 % 19.25 % 18.69 % 19.36 % 15.21 %
KRYS's Total Ranking # 694 # 704 # 336 # 621 # 740
Equity (TTM) in Millions 1,359 1,277 1,220 1,138 1,041
Seq. Equity Change 6.45 % 4.69 % 7.18 % 9.34 % 5.68 %
Seq. Net Income Change -2.08 % 8.82 % -35.24 % 107.04 % 7.28 %

Return On Equity Company Ranking
Within: No.
Industry # 12
Sector # 86
Overall # 694

Return On Equity Statistics
High Average Low
19.36 %
-5.78 %
-25.79 %
(Sep 30 2025)   (Dec 31 2022)





KRYS Annual Return On Equity (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2021
(Dec 31 2020)
2020
Total Equity in Millions 1,220 946 779 522 292
Y / Y Equity Change 28.87 % 21.54 % 49.1 % 78.79 % 43.94 %
Net Income in Millions 205 89 11 -140 -32
Y / Y Net Income Change 129.74 % 715.58 % - - -
Return On Equity 16.8 % 9.42 % 1.4 % -26.8 % -11.01 %





Annual Roe Comment
In 2025 ROE improved to 16.8 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KRYS's' Return on Equity at Yahoo Finance
KRYS's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KRYS's Competitors
Subscribers only: Roe for Krystal Biotech Inc 's Suppliers
Subscribers only: Return On Equity for KRYS's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %


Date modified: 2026-09-12T18:37:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.